Cystic Fibrosis Triplet Could Unblock EU Reimbursement Impasse

 
• By Sten Stovall

Cystic fibrosis specialist Vertex remains at loggerheads with HTAs in England and France over its product pricing, but hopes its triplet regimes can eventually break the impasse. 

Decision making
Vertex's Choice Of CF Triplet May Help Its EU Reimbursement Talks • Source: Shutterstock

More from Earnings

More from Business